HFA
ADAP

Hoover Financial Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Hoover Financial Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$8K Hold
1,766
– – ﹤0.01% 496
2021
Q1 		$8K Hold
1,766
– – ﹤0.01% 446
2020
Q4 		$11K Buy
+1,766
New +$9.6K ﹤0.01% 397
2020
Q3 		– Sell
-655
Closed -$7K – 193
2020
Q2 		$7K Buy
+655
New +$4.11K ﹤0.01% 368

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hoover Financial Advisors's ADAP Position: Q2 2021 in Review

Hoover Financial Advisors held its Adaptimmune Therapeutics (ADAP) position steady in Q2 2021 at 1,766 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #496.

Hoover Financial Advisors first reported a position in ADAP in Q2 2020 and has held it in 4 quarters since. The position peaked at $11K in Q4 2020. 82 funds tracked by Wall St. Rank hold ADAP as of Q2 2021.

  • Hoover Financial Advisors held 1,766 shares of Adaptimmune Therapeutics worth $8K as of Q2 2021.
  • Hoover Financial Advisors left its Adaptimmune Therapeutics share count unchanged in Q2 2021.
  • Adaptimmune Therapeutics made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #496 holding.
  • Hoover Financial Advisors first reported a position in Adaptimmune Therapeutics in Q2 2020 and has held it in 4 quarters since.
  • Hoover Financial Advisors's Adaptimmune Therapeutics position peaked at $11K in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.